Natarajan K - Search Results

1

Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.

Kapoor S, Natarajan K, Baldwin PR, Doshi KA, Lapidus RG, Mathias TJ, Scarpa M, Trotta R, Davila E, Kraus M, Huszar D, Tron AE, Perrotti D, Baer MR. Kapoor S, et al. Among authors: natarajan k. Clin Cancer Res. 2018 Jan 1;24(1):234-247. doi: 10.1158/1078-0432.CCR-17-1629. Epub 2017 Oct 26. Clin Cancer Res. 2018. PMID: 29074603 Free PMC article.

2

The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.

Bhullar J, Natarajan K, Shukla S, Mathias TJ, Sadowska M, Ambudkar SV, Baer MR. Bhullar J, et al. Among authors: natarajan k. PLoS One. 2013 Aug 14;8(8):e71266. doi: 10.1371/journal.pone.0071266. eCollection 2013. PLoS One. 2013. PMID: 23967177 Free PMC article.

3

Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication.

Natarajan K, Xie Y, Burcu M, Linn DE, Qiu Y, Baer MR. Natarajan K, et al. PLoS One. 2013 Sep 5;8(9):e74653. doi: 10.1371/journal.pone.0074653. eCollection 2013. PLoS One. 2013. PMID: 24040307 Free PMC article.

4

The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.

Mathias TJ, Natarajan K, Shukla S, Doshi KA, Singh ZN, Ambudkar SV, Baer MR. Mathias TJ, et al. Among authors: natarajan k. Invest New Drugs. 2015 Apr;33(2):300-9. doi: 10.1007/s10637-015-0205-y. Epub 2015 Jan 20. Invest New Drugs. 2015. PMID: 25597754 Free PMC article.

5

Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.

Doshi KA, Trotta R, Natarajan K, Rassool FV, Tron AE, Huszar D, Perrotti D, Baer MR. Doshi KA, et al. Among authors: natarajan k. Oncotarget. 2016 Jul 26;7(30):48280-48295. doi: 10.18632/oncotarget.10209. Oncotarget. 2016. PMID: 27374090 Free PMC article.

6

The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

Sen R, Natarajan K, Bhullar J, Shukla S, Fang HB, Cai L, Chen ZS, Ambudkar SV, Baer MR. Sen R, et al. Among authors: natarajan k. Mol Cancer Ther. 2012 Sep;11(9):2033-44. doi: 10.1158/1535-7163.MCT-12-0302. Epub 2012 Jul 9. Mol Cancer Ther. 2012. PMID: 22778153 Free PMC article.

7

The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.

Natarajan K, Bhullar J, Shukla S, Burcu M, Chen ZS, Ambudkar SV, Baer MR. Natarajan K, et al. Biochem Pharmacol. 2013 Feb 15;85(4):514-24. doi: 10.1016/j.bcp.2012.12.006. Epub 2012 Dec 19. Biochem Pharmacol. 2013. PMID: 23261525 Free PMC article.

8

Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Natarajan K, Xie Y, Baer MR, Ross DD. Natarajan K, et al. Biochem Pharmacol. 2012 Apr 15;83(8):1084-103. doi: 10.1016/j.bcp.2012.01.002. Epub 2012 Jan 11. Biochem Pharmacol. 2012. PMID: 22248732 Free PMC article. Review.

9

Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2.

Lapidus RG, Carter-Cooper BA, Sadowska M, Choi EY, Wonodi O, Muvarak N, Natarajan K, Pidugu LS, Jaiswal A, Toth EA, Rassool FV, Etemadi A, Sausville EA, Baer MR, Emadi A. Lapidus RG, et al. Among authors: natarajan k. Pharmaceuticals (Basel). 2016 Jan 19;9(1):4. doi: 10.3390/ph9010004. Pharmaceuticals (Basel). 2016. PMID: 26797621 Free PMC article.

10

Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells.

Xie Y, Nakanishi T, Natarajan K, Safren L, Hamburger AW, Hussain A, Ross DD. Xie Y, et al. Among authors: natarajan k. Biochim Biophys Acta. 2015 Mar;1849(3):317-27. doi: 10.1016/j.bbagrm.2015.01.003. Epub 2015 Jan 21. Biochim Biophys Acta. 2015. PMID: 25615818 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

729 results

Search Page